Citations

Clear

634 citation(s) found for "Hall, A".

Post–Kidney Transplant Hospitalizations and Long-Term Outcomes
Malhotra, Divyanshu , Alasfar, Sami , Thiessen‐Philbrook, Heather , Hall, Isaac E. , Doshi, Mona D. , Mohan, Sumit , Reese, Peter P. , Parikh, Chirag R. , Parikh, Chirag R , Mohan, Sumit

Mayo Clinic

Kidney360 | March 5, 2025 | Volume: 6 | Issue: 7 | Pages: 1158-1166

10.34067/kid.0000000759 | PMID 40042931 Get It

Key Points Nonimmunologic AKI-related rehospitalizations post–kidney transplant are associated with poorer long-term allograft and recipient outcomes. These data are not reported to United Network for Organ Sharing, and there are no datasets highlighting this important association; thus, our findings are valuable to clinicians. We hope to help the community create a cohort of higher risk transplant patients who need closer monitoring to potentially increase graft longevity Background AKI is associated with an increased risk of CKD and ESKD. However, only limited studies have investigated the effect of AKI episodes on kidney transplant outcomes. This study evaluated the effect of rehospitalization associated with nonimmunologic AKI on long-term outcomes. Data on rehospitalization with AKI after kidney transplant are not reported to United Network for Organ Sharing, and thus, there are no large datasets available to study this association. Methods We completed chart reviews of 989 deceased donor kidney transplant recipients transplanted from 2010 to 2014 at 13 transplant centers in the Deceased Donor Study Consortium. Rehospitalizations up to 5 years post-transplant were included. The cause of rehospitalizations was adjudicated by a transplant nephrologist on the basis of the discharge diagnosis. Primary outcomes were the effect of AKI-related rehospitalization on death-censored graft failure and all-cause mortality. We excluded rehospitalizations because of acute rejection from the primary analysis. The cohort was linked to data from Organ Procurement and Transplantation Network supplied by United Network for Organ Sharing. Time-varying cox-proportional hazard models were used to examine the association between rehospitalization and outcomes. Results We identified 200 (20%) recipients with at least one rehospitalization associated with AKI, 516 (52%) with rehospitalizations without AKI, and 273 (28%) without a rehospitalization post-transplant. Delayed graft function, donor age, and kidney donor profile index score differed between the three groups. We found a higher risk of death censored graft failure adjusted hazard ratio (aHR) 7.5 (95% confidence interval [CI], 4.0 to 13.8), all-cause graft failure aHR 6.7 (95% CI, 4.2 to 10.8), and all-cause mortality aHR 5.7 (95% CI, 2.7 to 11.8) for rehospitalizations associated with AKI compared with no rehospitalization. The non-AKI rehospitalizations also had significantly higher rates of measured outcomes; however, the associations were not as strong. Conclusions AKI rehospitalizations were associated with a significantly increased risk of poorer graft outcomes, and thus, closer follow-up of this high-risk group is warranted.
Comparative meta-analysis of microsurgery versus endovascular therapy and bypass versus nonbypass techniques for blister-like aneurysms: enigmas of the supraclinoid internal carotid artery
Pennington, Zach , Patel, Saarang, Rahmani, Redi , Lawton, Michael T., Pennington, Zach , Brown, Nolan J. , Patel, Saarang , Tafreshi, Ali, Gendreau, Julian , Catapano, Joshua S , Lawton, Michael T.

Mayo Clinic

Journal of Neurosurgery | February 21, 2025 | Volume: 143 | Issue: 1 | Pages: 243-254

10.3171/2024.8.jns232241 | PMID 39983119 Get It

OBJECTIVE Blister aneurysms of the internal carotid artery (ICA) have high associated mortality rates and are challenging due to their friable wall and poorly defined neck. Microsurgical and endovascular treatment options have been suggested, including bypass of the parent vessel to exclude the aneurysm. The goal of this study was to evaluate the safety and efficacy of microsurgical versus endovascular interventions. Additionally, for patients treated with open surgery, the outcomes of bypass were compared to nonbypass techniques. METHODS Three databases were systematically queried for primary studies comparing microsurgery to endovascular therapy and assessing bypass versus nonbypass treatment modalities for blister aneurysms of the ICA. All relevant studies published between 2000 and 2023 were eligible for inclusion. All articles were screened against title and abstract by 2 authors, as were those eligible for full-text assessment. Ultimately, relevant data from all included studies were pooled for meta-analysis in which the Mantel-Haenszel method with random-effects modeling was used. RESULTS Among the 504 cases reported across 24 studies, 182 (35.1%) blister aneurysms of the ICA were surgically treated, whereas 337 (64.9%) involved endovascular treatment. There were 235 (46.6%) female patients in the cohort. Functional outcomes were comparable between groups, with 83% of surgically treated patients and 85% of endovascularly treated patients achieving a favorable outcome (p > 0.05). Among the 7 studies (178 patients) comparing bypass to nonbypass microsurgery, rates of postoperative bleeding, ischemic infarct, vasospasm, recurrence, favorable outcomes, and mortality were comparable for bypass (n = 54, 30.3%) and nonbypass groups (n = 124, 69.7%). CONCLUSIONS Blister aneurysms of the ICA are rare intracranial aneurysms that are difficult to treat with microsurgical and endovascular techniques. Considering only patients treated with open surgery, there appears to be no significant difference in complication profile or functional outcomes between patients undergoing bypass or alternative microsurgical techniques. However, it must be noted that the complex nature of bypass procedures means that much of the data granularity is lost on meta-analysis, suggesting that additional investigations comparing bypass to other open microsurgical techniques may be merited. Similarly, future studies should determine the limitations of dual antiplatelet therapy in endovascular treatment and the efficacy of different numbers and types of overlapping, flow-diverting devices.
Executive Summary of a Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D. , Chanques, Gérald , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D , Kho, Michelle E. , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Ross, Chris, Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e701-e710

10.1097/ccm.0000000000006573 | PMID 39982138 Get It

A Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D., Chanques, Gérald , Kho, Michelle E. , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D. , Girard, Timothy D , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e711-e727

10.1097/ccm.0000000000006574 | PMID 39982143 Get It

RATIONALE: Critically ill adults are at risk for a variety of distressing and consequential symptoms both during and after an ICU stay. Management of these symptoms can directly influence outcomes. OBJECTIVES: The objective was to update and expand the Society of Critical Care Medicine’s 2018 Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. PANEL DESIGN: The interprofessional inclusive guidelines task force was composed of 24 individuals including nurses, physicians, pharmacists, physiotherapists, psychologists, and ICU survivors. The task force developed evidence-based recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Conflict-of-interest policies were strictly followed in all phases of the guidelines, including task force selection and voting. METHODS: The task force focused on five main content areas as they pertain to adult ICU patients: anxiety (new topic), agitation/sedation, delirium, immobility, and sleep disruption. Using the GRADE approach, we conducted a rigorous systematic review for each population, intervention, control, and outcome question to identify the best available evidence, statistically summarized the evidence, assessed the quality of evidence, and then performed the evidence-to-decision framework to formulate recommendations. RESULTS: The task force issued five statements related to the management of anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adults admitted to the ICU. In adult patients admitted to the ICU, the task force issued conditional recommendations to use dexmedetomidine over propofol for sedation, provide enhanced mobilization/rehabilitation over usual mobilization/rehabilitation, and administer melatonin. The task force was unable to issue recommendations on the administration of benzodiazepines to treat anxiety, and the use of antipsychotics to treat delirium. CONCLUSIONS: The guidelines task force provided recommendations for pharmacologic management of agitation/sedation and sleep, and nonpharmacologic management of immobility in critically ill adults. These recommendations are intended for consideration along with the patient’s clinical status.
Verdiperstat in Amyotrophic Lateral Sclerosis
Hayden, Douglas * deceased, Lai, Po-Ying, Donahue, Rachel, Chen, Hao-Wun, Nm, Mathai, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martín, Alan, Greene, Ericka , Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew B. , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep , Walk, David , Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny A. , Soliven, Betty , Roos, Raymond, Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Fournier, C. , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, Liam, Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patterson, J.C., Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, M., Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Santiago, Diana De, Félix, Adrián, Garrett, Karly, Hamilton, Jenny, Khan, Kamran, Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Andrews, Jinsy , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joseph , Young, Eufrosina , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alex, Hall, Meghan, Kittle, Gale, Connolly, Mariah, D’Agostino, Derek, Tustison, Eric, Scirocco, Erica, Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Heitzman, Daragh, Ajroud‐Driss, Senda , Appel, Stanley H. , Shroff, Sheetal , Katz, Jonathan, Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Olney, Nicholas , Miller, Timothy M. , Fernandes, Joseph Americo, Ilieva, Hristelina , Jawdat, Omar, Weiss, Michael D. , Foster, Laura A. , Owegi, Margaret, Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Fee, Dominic , Lewis, Richard A. , Rosenfeld, Jeffrey , Johnson, Kristin, Elliott, Matthew, Kasarskis, Edward J. , Rutkove, Seward B. , McIlduff, Courtney, Bedlack, Richard , Elman, Lauren , Goyal, Namita , Rezania, Kourosh , Twydell, Paul, Benatar, Michael , Glass, Jonathan D. , Jones, Vovanti , Zilliox, Lindsay , Wymer, James , Beydoun, Said R., Shah, Jaimin , Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Nayar, Shakti, Donohue, Mary V., Grossman, Katheryn, Campbell, Daniel , Qureshi, Irfan , Babu, Suma , Group, HEALEY ALS Platform Trial Study, Maragakis, Nicholas J. , Scirocco, Erica , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Maragakis, Nicholas , Bedlack, Richard S , Walk, David , Hayden, Douglas, Wang, Jianing , Mathai, N. M., Kolb, Stephen J. , Szymanski, April L., Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Diaz, Frank , Shrilla, David, Rakočević, Goran , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Robbins, Nathaniel M. , Oskarsson, Björn , Chuquilin, Miguel , McNeely, Whitney, Bobenhouse, James, Staff, Nathan P. , Arroyave, Luisa, Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Estes, Michaela, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Jordan, Boglarka, Kolvek, Taylor, Korin, Alexander, Nguyen, Joey, Novak, Ilya, Ostrow, Joe, Palillo, Jack, Patel, Payal, Patterson, Janae, Phan, Minh, Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Felix, Adrian, Khan, Kamran, Lovett, Marlee, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Paganoni, Sabrina , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Berry, James D. , Giacomelli, Elisa , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Ladha, Shafeeq , Newman, Daniel S., Swenson, Andrea , Caress, James B. , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Granit, Volkan , Donohue, Mary, Cudkowicz, Merit , Group, HEALEY ALS Platform Trial Study

Mayo Clinic

JAMA Neurology | February 17, 2025 | Volume: 82 | Issue: 4 | Pages: 333

10.1001/jamaneurol.2024.5249 | PMID 40067754 Get It

ImportanceMyeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via reduced neuroinflammation and oxidative stress.ObjectiveTo determine the safety, tolerability, and efficacy of verdiperstat, a selective myeloperoxidase inhibitor, in ALS.Design, Settings, and ParticipantsVerdiperstat was tested as a regimen of the HEALEY ALS Platform Trial, a multicenter, double-blind, perpetual platform design, randomized clinical trial, with sharing of trial infrastructure and placebo data across multiple regimens. The study was conducted at 54 ALS referral centers across the US from July 2020 to April 2022. Adult participants with a diagnosis of clinically possible, probable, laboratory-supported probable, or definite ALS defined by the revised El Escorial criteria were randomized to verdiperstat or regimen-specific placebo. An additional group of participants concurrently randomized to placebo from other regimens was included in the analyses.InterventionsEligible participants were randomized in a 3:1 ratio to receive oral verdiperstat, 600 mg, twice daily or matching placebo for a planned placebo-controlled duration of 24 weeks.Main Outcomes and MeasuresThe primary efficacy outcome was change from baseline through week 24 in disease severity, as measured by a joint model of ALS Functional Rating Scale–Revised and survival, with the treatment effect quantified by the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression of verdiperstat relative to placebo.ResultsA total of 167 participants (mean [SD] age, 58.5 [11.4] years; 59 [35.3%] female; 108 [64.6%] male) were randomized to either verdiperstat (126 [75.4%]) or to placebo (41 [25.6%]). Among the participants randomized to the verdiperstat regimen, 130 (78%) completed the trial. The estimated DRR was 0.98 (95% credible interval, 0.77-1.24; posterior probability = 0.57 for slowing of disease progression [DRR <1]). Verdiperstat was estimated to slow progression by 2% vs placebo (95% credible interval, −23% to 24%; posterior probability 0.57). Verdiperstat was overall safe and well tolerated. Common adverse events in the verdiperstat group were nausea, insomnia, and elevated thyrotropin levels.Conclusions and RelevanceResults demonstrate that treatment with verdiperstat was unlikely to alter disease progression in ALS.Trial RegistrationClinical Trial Identifiers: NCT04297683 and NCT04436510
Pridopidine in Amyotrophic Lateral Sclerosis
Hayden, Douglas, Lai, Po-Ying, Donahue, Rachel, Chen, H.Y., Mathai, Nithya, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Ghasemi, Mehdi, Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny, Soliven, Betty , Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Glass, Jonathan D. , Fournier, Christina , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patel, Payal , Patterson, Janae, Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Felix, A. John William , Garrett, Karly, Hamilton, Jenny, Khan, Kamran , Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joe , Heiman‐Patterson, Terry , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alexander , Hall, Meghan, Kittle, Gale, Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica , Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Ajroud‐Driss, Senda , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H. , Shroff, Sheetal , Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew, Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael , Jones, Vovanti , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Leitner, Melanie , Chen, Kelly , Goldberg, Y. Paul, Cohen, Yaël C. , Geva, Michal , Hayden, Michael R. , Group, HEALEY ALS Platform Trial Study, Scirocco, Erica , Martinez-Thompson, Jennifer, Simmons, Zachary , Bedlack, Richard S , Walk, David , Wang, Jianing , Mathai, N. M., Kolb, Stephen J. , Szymanski, April L., Martin, Alan, Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Harms, Matthew B. , Diaz, Frank , Shrilla, David, Rakočević, Goran , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep, Rutkove, Seward B. , Rao, Pooja, Robbins, Nathaniel M. , Granit, Volkan , Chuquilin, Miguel , McNeely, Whitney, Bobenhouse, James, Staff, Nathan P. , Arroyave, Luisa, Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Kolvek, Taylor, Korin, Alexander, Ostrow, Joe, Palillo, Jack, Phan, Minh, Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Garrett, Karly, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Shefner, Jeremy M. , Oskarsson, Björn , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Berry, James D. , Babu, Suma , Giacomelli, Elisa , Maragakis, Nicholas J. , Mill, Jonathan , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Goldberg, Y. Paul, Paganoni, Sabrina , Cudkowicz, Merit

Mayo Clinic

JAMA | February 17, 2025 | Volume: 333 | Issue: 13 | Pages: 1128

10.1001/jama.2024.26429 | PMID 40067755 Get It

ImportanceAmyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.ObjectiveTo determine the effects of pridopidine, a σ1-receptor agonist, in ALS.Design, Settings, and ParticipantsPridopidine was tested as a regimen of the HEALEY ALS Platform Trial, a phase 2/3, multicenter, randomized, double-blind, platform trial. The study was conducted at 54 sites in the US from January 2021 to July 2022 (final follow-up, July 14, 2022). A total of 163 participants with ALS were randomized to receive pridopidine or placebo. An additional 122 concurrently randomized participants were assigned to receive placebo in other regimens and included in the analyses.InterventionsEligible participants were randomized 3:1 to receive oral pridopidine 45 mg twice daily (n = 121) or matching oral placebo (n = 42) for a planned duration of 24 weeks.Main Outcomes and MeasuresThe primary efficacy outcome was change from baseline through week 24 in ALS disease severity, analyzed using a bayesian shared parameter model, which has components for function (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-R]) and survival that were linked through an integrated estimate of treatment-dependent disease slowing across these 2 components. This was denoted as the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression on pridopidine relative to placebo. There were 5 key secondary end points: time to 2-point or greater reduction in ALSFRS-R total score among participants with bulbar dysfunction at baseline, rate of decline in slow vital capacity among participants with bulbar dysfunction at baseline, percentage of participants with no worsening in the ALSFRS-R bulbar domain score, time to 1-point or greater change in the ALSFRS-R bulbar domain score, and time to death or permanent assisted ventilation.ResultsAmong 162 patients (mean age, 57.5 years; 35% female) who were randomized to receive the pridopidine regimen and included in the primary efficacy analysis, 136 (84%) completed the trial. In the primary analysis comparing pridopidine vs the combined placebo groups, there was no significant difference between pridopidine and placebo in the primary end point (DRR, 0.99 [95% credible interval, 0.80-1.21]; probability of DRR <1, 0.55) and no differences were seen in the components of ALSFRS-R or survival. There was no benefit of pridopidine on the secondary end points. In the safety dataset (pridopidine, n = 121; placebo, n = 163), the most common adverse events were falls (28.1% vs 29.3%, respectively) and muscular weakness (24.0% vs 31.7%, respectively).Conclusions and RelevanceIn this 24-week study, pridopidine did not impact the progression of ALS.Trial RegistrationClinicalTrials.gov Identifiers: NCT04297683, NCT04615923
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
Fournier, Christina , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joe , Ajroud‐Driss, Senda , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alexander , Hall, Meghan, Kittle, Gale, Babu, Suma , Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica , Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H., Shroff, Sheetal , Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Miller, Timothy M. , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew, Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael, Jones, Vovanti , Glass, Jonathan D. , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Patel, Shital , Mahoney, Paul, Duda, Petra W., Group, HEALEY ALS Platform Trial Study, Hayden, Douglas * deceased, Lai, Po-Ying, Donahue, Rachel A., Chen, Hao-Wun, Mathai, Nithya, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Dimachkie, Mazen M. , Brown, Robert H. , Ghasemi, Mehdi, Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Rutkove, Seward B. , Mundwiler, Andrew, Meyer, Jenny, Soliven, Betty , Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Staff, Nathan P. , Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patel, Payal , Patterson, Janae, Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Felix, A. John William , Garrett, Karly, Hamilton, Jenny, Khan, Kamran , Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Maragakis, Nicholas J. , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Staff, Nathan P , Maragakis, Nicholas , Bedlack, Richard S , Dimachkie, Mazen M , Walk, David , Paganoni, Sabrina , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Berry, James D. , Giacomelli, Elisa , Appel, Stanley H. , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Harvey, Brittany, Mahoney, Paul, Cudkowicz, Merit , Group, HEALEY ALS Platform Trial Study, Hayden, Douglas * deceased, Donahue, Rachel A., Chen, Hao-Wun, Wang, Jianing, Mathai, N. M., Kolb, Stephen J. , Szymanski, April, Martin, Alan, Liao, Bing, Riley, Kristen M., Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Ghasemi, Mehdi , Pasinelli, Piera , Gutmann, Ludwig , Harms, Matthew B. , Diaz, Frank , Rakočević, Goran , Quinn, Colin , Borg, David, Kaur, Jasdeep, Rao, Pooja, Robbins, Nathaniel M. , Granit, Volkan , Oskarsson, Björn , Chuquilin, Miguel , Arroyave, Luisa, Bailey, Abbey, Bulat, Allison , Hurwitz, Samuel, Irwin, Liam, Jordan, Boglarka, Korin, Alexander, Novak, Ilya, Patterson, Janae, Phan, Minh, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Wahab, Yusra, Wright, Spencer, Garrett, Karly, Lovett, Marlee, Nelson, Linda, Pabon, Marissa, Bolger, Patrick, Fetouh, Ahmed, Kennedy, Julie

Mayo Clinic

JAMA Network Open | February 17, 2025 | Volume: 8 | Issue: 2 | Pages: e2459058

10.1001/jamanetworkopen.2024.59058 | PMID 39960672 Get It

Importance The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective To determine the effects of zilucoplan, an inhibitor of complement C5, in individuals with ALS. Design, Setting, and Participants Zilucoplan was tested as regimen A of the HEALEY ALS Platform Trial, a phase 2 to 3 multicenter, randomized, double-blind, placebo-controlled perpetual platform clinical trial with sharing of trial infrastructure and placebo data across multiple regimens. Regimen A was conducted from August 17, 2020, to May 4, 2022. A total of 162 participants were randomized to receive zilucoplan (122 [75.3%]) or regimen-specific placebo (40 [24.7%]). An additional 124 concurrently randomized participants were randomized to receive placebo in other regimens. Interventions Eligible participants were randomized in a 3:1 ratio to receive zilucoplan or matching placebo within strata of edaravone and/or riluzole use for a planned duration of 24 weeks. Active drug (zilucoplan, 0.3 mg/kg) and placebo were provided for daily subcutaneous dosing. Main Outcomes and Measures The primary end point was change in disease severity from baseline through 24 weeks as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) total score and survival, analyzed using a bayesian shared-parameter model and reported as disease rate ratio (DRR; <1 indicating treatment benefit). The study included prespecified rules for early stopping for futility. Outcome analyses were performed in the full analysis set comparing the zilucoplan group with the total shared placebo group (n = 164). Results Among the 162 participants who were randomized (mean [SD] age, 59.6 [11.3]; 99 [61.1%] male), 115 (71.0%) completed the trial. The estimated DRR common to ALSFRS-R and survival was 1.08 (95% credible interval, 0.87-1.31; posterior probability of superiority, 0.24). The trial was stopped early for futility. No unexpected treatment-related risks were identified. Conclusions and Relevance In this randomized clinical trial of zilucoplan in ALS, treatment did not alter disease progression. The adaptive platform design of the HEALEY ALS Platform Trial made it possible to test a new investigational product with efficient use of time and resources. Trial Registration ClinicalTrials.gov Identifier: NCT04297683
CNM-Au8 in Amyotrophic Lateral Sclerosis
Hayden, Douglas, Lai, Po-Ying, Donahue, Rachel, Chen, H., Mathai, N. M., Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew, Burford, Matthew, Shrilla, David, Jones, Sarah, Solórzano, Guillermo, Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny, Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Carberry, Nathan , Govindarajan, Raghav , Fournier, Christina , Darki, Leila, Rodriguez, Rodrigo , Chuguilin, Miguel, McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Staff, N., Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, M L, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patterson, Janae, Phan, Minh, Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Félix, Adrián, Garrett, Karly, Hamilton, Jenny, Lovett, Marlee, Nelson, Linda S., Pabón, M. Vargas, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Maragakis, Nicholas J. , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joseph , Stommel, Elijah W. , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alex, Hall, Meghan, Kittle, Gale, Babu, Suma , Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica, Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Ajroud‐Driss, Senda , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H. , Shroff, Sheetal , Felice, Kevin J. , Simmons, Zachary, Miller, Timothy M. , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew , Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey V. , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael, Jones, Vovanti , Glass, Jonathan D. , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Rynders, Austin, Evan, Jacob, Evan, Jeremy, Hartford, Alan , Sepassi, Marjan , Ho, Karen S. , Glanzman, Robert , Hotchkin, Michael T. , Group, HEALEY ALS Platform Trial Study, Simmons, Zachary , Scirocco, Erica , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Maragakis, Nicholas , Bedlack, Richard S , Walk, David , Wang, Jianing , Kolb, Stephen J. , Szymanski, April L., Martin, Alan, Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Harms, Matthew, Diaz, Frank , Shrilla, David, Rakočević, Goran , Li, Xiaoyan , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep, Rutkove, Seward B. , Rao, Pooja, Mullen, Jeffrey, Robbins, Nathaniel M. , Granit, Volkan , Oskarsson, Björn , McNeely, Whitney, Bobenhouse, James, Arroyave, Luisa, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Estes, Michaela, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Kolvek, Taylor, Korin, Alexander, Li, Haining, Nguyen, Joey, Ostrow, Joe, Palillo, Jack, Patel, Payal , Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Santiago, Diana De, Felix, Adrian, Garrett, Karly, Khan, Kamran, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Berry, James D. , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Giacomelli, Elisa , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Elliott, Matthew, Johnson, Kristin, Cohen, Jeffrey Allen , Greenberg, Benjamin , Paganoni, Sabrina , Cudkowicz, Merit

Mayo Clinic

JAMA | February 17, 2025 | Volume: 333 | Issue: 13 | Pages: 1138

10.1001/jama.2024.27643 | PMID 40067821 Get It

Importance Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride into NAD + , resulting in an increase of cellular adenosine triphosphate production. Objective To determine the effects of CNM-Au8 on ALS disease progression. Design, Setting, and Participants CNM-Au8 was tested as a regimen of the HEALEY ALS Platform Trial, a phase 2/3, multicenter, randomized, double-blind platform trial. The study was conducted at 54 sites in the US from July 2020 to March 2022 (final follow-up, March 17, 2022). A total of 161 participants with ALS were randomized to receive CNM-Au8 (n = 120) or regimen-specific placebo (n = 41). Data from 123 concurrently randomized placebo participants in other regimens were combined for analyses. Interventions Eligible participants were randomized in a 3:3:2 ratio to receive CNM-Au8 60 mg daily (n = 61), CNM-Au8 30 mg daily (n = 59), or matching placebo (n = 41) for 24 weeks. Main Outcomes and Measures The primary efficacy outcome was change from baseline through week 24 in ALS disease severity measured by a bayesian shared parameter model of function (based on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale) and survival, which provided an estimate of the rate of disease progression measured by the disease rate ratio (DRR), with a DRR of less than 1 indicating treatment benefit. Secondary end points included a Combined Assessment of Function and Survival using a joint-rank test, rate of decline in slow vital capacity (percent predicted), and survival free of permanent assisted ventilation. Results Among 161 participants who were randomized within the CNM-Au8 regimen (mean age, 58.4 years; 61 [37.9%] female), 145 (90%) completed the trial. In the primary analysis comparing the combined CNM-Au8 dosage groups vs the combined placebo groups, the primary end point (DRR, 0.97 [95% credible interval, 0.783-1.175]; posterior probability of DRR <1, 0.65) and the 3 secondary end points suggested no benefit or harm of CNM-Au8. In the active (n = 120) vs placebo (n = 163) groups, the most common adverse events were diarrhea (23 [19%] vs 12 [7%]), nausea (17 [14.2%] vs 14 [8.6%]), fatigue (12 [10.8%] vs 30 [18.4%]), and muscular weakness (24 [20%] vs 45 [27.6%]). Conclusions and Relevance No benefit of CNM-Au8 on ALS disease progression was observed at 24 weeks. Trial Registration ClinicalTrials.gov Identifiers: NCT04297683 , NCT04414345
Lack of Standardized Coding Limits Accuracy of Electronic Clinical Quality Measure for Pulmonary Embolism Diagnosis
Keenan, Megan , Dykhoff, Hayley J. , Hall, Marie Boas, Campbell, Kyle N., Cahill, Emily , Hanson, Ryan , McEvoy, Dustin , He, Wei , Kreuziger, Lisa Baumann , Hall, Marie, Dutta, Sayon , Rosovsky, Rachel , Houghton, Damon E.

Mayo Clinic

American Journal of Medical Quality | February 11, 2025 | Volume: 40 | Issue: 2 | Pages: 38-43

10.1097/jmq.0000000000000223 | PMID 39930618 Get It

Guidelines for diagnosing pulmonary embolism (PE) start with a risk assessment using a pretest probability (PTP) tool, followed by D-dimer testing or computed tomography pulmonary angiography (CTPA) depending on risk. The project aimed to develop an electronic clinical quality measure (eCQM) to encourage broader use of a validated PTP scoring tool in emergency departments (EDs) to more accurately diagnose PE and to reduce unnecessary CTPAs. To identify a value set to accurately identify CTPA and abnormal D-dimer tests using standard classification systems and clinical vocabularies (ie, Current Procedural Terminology [CPT], Logical Observation Identifiers Names and Codes [LOINC], systematized nomenclature of medicine clinical terms [SNOMED CT]) across 3 academic United States health care systems. A comprehensive value set to identify CTPAs was selected, which contained 31 codes. Additionally, each health care system had unique, site-specific codes to more granularly identify CTPAs. Three health care systems representing 38 EDs from across the country submitted data from all ED encounters between September 12, 2022, and January 11, 2023. Imaging types were reviewed from each of the CPT codes and LOINC. The project evaluated whether a D-dimer was obtained using CPT and LOINC and whether the D-dimer result was elevated using SNOMED CT. The number of ED encounters, PTP use, and diagnosis of PE using different codes were determined. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value for selected codes were calculated. Over a 4-month study period, 270,214 encounters were included from 38 EDs. 11,794 ED encounters with CTPAs during the study period, using the site-specific codes were identified. The comprehensive value set had a PPV of 63.4%. Restricting the CTPA value set to CPT code 71275 or LOINC 88322-3 improved the PPV to 82% with 100% sensitivity and 99% specificity. The restricted value set captured the highest proportion of relevant site-specific codes. D-dimer values were identified using LOINC codes 48065-7 and 91556-1 at Site 1 and 48067-3 at Site 2. SNOMED CT codes were not used at any site to identify elevated D-dimer results. Different D-dimer tests with different normal ranges were used at each site, and only one site provided an abnormal flag for D-dimer results. Heterogeneity in the use of nationally standardized codes for labs and imaging tests limits the ability to measure and compare quality across health care organizations for CTPA and D-dimer results. Restricting the identification of CTPA to CPT Code 71275 or LOINC 88322-3 resulted in high sensitivity and specificity, but false positives remain. Additionally, coding for an abnormal D-dimer test result is not standardized across institutions. Therefore, the currently available value sets cannot be used to develop eCQMs whose aim is to evaluate whether CTPA is ordered appropriately based on the PTP risk level and laboratory testing.
Characterizing Rates of Post-Radiotherapy Seizure Control in Patients with Cerebral Arteriovenous Malformations: A Systematic Review and Meta-analysis
Patel, Saarang, Ryvlin, Jessica , Sahyouni, Ronald , Khalessi, Alexander A., Brown, Nolan J. , Pennington, Zach , Patel, Saarang , Michalopoulos, Giorgos D. , Martini, Michael L. , Ben‐Haim, Sharona

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803389 Get It